TNFi effective in nonradiographic axial SpA

Long-term adalimumab therapy in patients with nonradiographic axial spondyloarthritis provides sustained clinical and functional improvements with no additional safety issues. The three-year, open label extension of the ABILITY-1 trial found ‘similar and sustained’ improvements in the Ankylosing Spondylitis Disease Activity Score (ASDAS) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). This was consistent in ...

Already a member?

Login to keep reading.

© 2021 the limbic